NeuroPace Statistics
Total Valuation
NeuroPace has a market cap or net worth of $496.67 million. The enterprise value is $514.90 million.
| Market Cap | 496.67M |
| Enterprise Value | 514.90M |
Important Dates
The last earnings date was Tuesday, August 11, 2026, after market close.
| Earnings Date | Aug 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
NeuroPace has 34.32 million shares outstanding. The number of shares has increased by 8.60% in one year.
| Current Share Class | 34.32M |
| Shares Outstanding | 34.32M |
| Shares Change (YoY) | +8.60% |
| Shares Change (QoQ) | +1.15% |
| Owned by Insiders (%) | 3.90% |
| Owned by Institutions (%) | 70.36% |
| Float | 25.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.64 |
| Forward PS | 4.49 |
| PB Ratio | 41.75 |
| P/TBV Ratio | 41.80 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.81 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.94, with a Debt / Equity ratio of 5.88.
| Current Ratio | 4.94 |
| Quick Ratio | 3.82 |
| Debt / Equity | 5.88 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1.92 |
Financial Efficiency
Return on equity (ROE) is -103.27% and return on invested capital (ROIC) is -8.78%.
| Return on Equity (ROE) | -103.27% |
| Return on Assets (ROA) | -7.47% |
| Return on Invested Capital (ROIC) | -8.78% |
| Return on Capital Employed (ROCE) | -15.26% |
| Weighted Average Cost of Capital (WACC) | 13.94% |
| Revenue Per Employee | $486,332 |
| Profits Per Employee | -$86,882 |
| Employee Count | 220 |
| Asset Turnover | 1.05 |
| Inventory Turnover | 1.40 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +69.04% in the last 52 weeks. The beta is 1.94, so NeuroPace's price volatility has been higher than the market average.
| Beta (5Y) | 1.94 |
| 52-Week Price Change | +69.04% |
| 50-Day Moving Average | 15.42 |
| 200-Day Moving Average | 15.32 |
| Relative Strength Index (RSI) | 46.61 |
| Average Volume (20 Days) | 254,460 |
Short Selling Information
The latest short interest is 822,126, so 2.40% of the outstanding shares have been sold short.
| Short Interest | 822,126 |
| Short Previous Month | 874,337 |
| Short % of Shares Out | 2.40% |
| Short % of Float | 3.21% |
| Short Ratio (days to cover) | 4.45 |
Income Statement
In the last 12 months, NeuroPace had revenue of $106.99 million and -$19.11 million in losses. Loss per share was -$0.57.
| Revenue | 106.99M |
| Gross Profit | 82.79M |
| Operating Income | -12.14M |
| Pretax Income | -16.17M |
| Net Income | -19.11M |
| EBITDA | -11.88M |
| EBIT | -12.14M |
| Loss Per Share | -$0.57 |
Balance Sheet
The company has $51.70 million in cash and $69.93 million in debt, with a net cash position of -$18.23 million or -$0.53 per share.
| Cash & Cash Equivalents | 51.70M |
| Total Debt | 69.93M |
| Net Cash | -18.23M |
| Net Cash Per Share | -$0.53 |
| Equity (Book Value) | 11.88M |
| Book Value Per Share | 0.35 |
| Working Capital | 68.76M |
Cash Flow
In the last 12 months, operating cash flow was -$11.24 million and capital expenditures -$369,000, giving a free cash flow of -$11.61 million.
| Operating Cash Flow | -11.24M |
| Capital Expenditures | -369,000 |
| Depreciation & Amortization | 260,000 |
| Net Borrowing | -133,000 |
| Free Cash Flow | -11.61M |
| FCF Per Share | -$0.34 |
Margins
Gross margin is 77.38%, with operating and profit margins of -11.34% and -17.86%.
| Gross Margin | 77.38% |
| Operating Margin | -11.34% |
| Pretax Margin | -15.12% |
| Profit Margin | -17.86% |
| EBITDA Margin | -11.10% |
| EBIT Margin | -11.34% |
| FCF Margin | n/a |
Dividends & Yields
NeuroPace does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.60% |
| Shareholder Yield | -8.60% |
| Earnings Yield | -3.85% |
| FCF Yield | -2.34% |
Analyst Forecast
The average price target for NeuroPace is $20.22, which is 39.74% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $20.22 |
| Price Target Difference | 39.74% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 15.05% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
NeuroPace has an Altman Z-Score of -3.45 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.45 |
| Piotroski F-Score | 2 |